20 results about "Appetite suppressing" patented technology

The application discloses application of O-acyl-alpha-hydroxy acid compounds in weight loss and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine use and functional food development. The O-acyl-alpha-hydroxy acid compounds can inhibit weight growth of high-fat diet-induced obese model mice and reduce body fat. Compared with GLP-1 receptor weight loss drugs which achieve the effect of reducing weight by inhibiting appetite, the O-acyl-alpha-hydroxy acid compounds are not dependent on appetite inhibition, and can reduce side effects such as gastrointestinal discomfort and muscle loss caused by inhibiting appetite. When combined or sequentially administered with GLP-1 drugs, the O-acyl-alpha-hydroxy acid compounds can maintain or enhance the weight loss effect while improving the side effects caused by GLP-1, and can prevent the risk of significant weight rebound after stopping GLP-1 by maintaining body weight. The application provides a safe and effective new strategy for weight loss and lipid reduction.

This invention discloses the application of α-hydroxyisocaproic acid in weight loss and lipid reduction, belonging to the fields of biopharmaceutical manufacturing, biomedical applications, and functional food development. This invention confirms the application of α-hydroxyisocaproic acid in weight loss; this compound can inhibit weight gain in high-fat diet-induced obese mouse models, reduce body fat, and decrease the area of ​​adipocytes in high-fat diet-induced obese mouse models. Compared to GLP-1 receptor weight-loss drugs that reduce weight by suppressing appetite, the compound α-hydroxyisocaproic acid intervenes in and prevents obesity by accelerating fat metabolism, thereby achieving weight reduction. This invention provides a safe and effective new strategy for weight loss and lipid reduction.

The invention relates to the technical field of health-care products, and particularly discloses a roselle-containing composition and a preparation method thereof, and the roselle-containing composition comprises the following components: a roselle extract, a cocoa extract, coating protein, a fermentation compound and auxiliary materials; the added roselle extract is subjected to multi-step pretreatment, the extraction rate and stability of active ingredients are improved, and the polarity of the roselle extract can be adjusted by adopting a composite solvent for extraction, so that the bioavailability is improved; the added cocoa extract can reduce oxidation of anthocyanin, and the cocoa extract and the roselle extract are synergistically used for reducing blood fat by inhibiting lipase activity and adjusting cholesterol; the fermentation compound can generate urolithin A, pueraria peptide and perillyl alcohol to further assist in reducing blood fat, and the coating protein improves the stability and absorption efficiency of the roselle extract; the auxiliary materials can improve the bioavailability of the active components of the raw materials, and the prepared composition has the effects of inhibiting appetite, promoting lipolysis, inhibiting fat absorption and reducing blood fat through synergistic effects of all the components.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a first composition comprising a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures, a crosslinking compound, a foaming agent and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, a second composition comprising citric acid. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The invention relates to the technical field of traditional Chinese medicine extracts, in particular to an application of a ligusticum wallichii alcohol extract and an active monomer thereof in preparation of a product for relieving or treating food-borne obesity. Experimental research finds that when the ligusticum wallichii alcohol extract is singly used, the mRNA expression level of POMC in hypothalamus of a high-fat diet induced food-borne obesity mouse can be reduced, the alpha-MSH level in the hypothalamus can be improved, appetite can be effectively inhibited, body weight can be reduced, meanwhile, the number of lipid droplets in the liver can be reduced, and the ligusticum wallichii alcohol extract has the effects of relieving and treating food-borne obesity, preventing and treating hyperlipidemia and the like. And the application potential of liver tissues is improved, and a new direction and theoretical support are provided for treating food-borne obesity and expanding the medication range of ligusticum wallichii.

The present application relates to the field of medicine and health food evaluation, in order to solve the problem of lacking the method for evaluating the appetite regulating effect of medicine and health food in the prior art, a method for evaluating the appetite regulating effect of medicine and health food is provided, different concentrations of the sample to be tested are given to Nile red enteric labeled zebrafish by water dissolution, and the zebrafish are cultured for 24-36 h, a normal control group is set at the same time, the intestinal fluorescence intensity of the zebrafish in each group is analyzed, the sample to be tested is given to the zebrafish by water dissolution, and the zebrafish are cultured for 48-72 h, a normal control group is set at the same time, egg yolk powder is fed for 1-3 h, part of the zebrafish in each group are selected, the sum of the intestinal opacity and the tail blood vessel staining intensity of the zebrafish are analyzed, the remaining zebrafish continue to be cultured for 24-48 h, and the intestinal short-chain fatty acid fluorescence intensity and the expression of appetite inhibiting genes and appetite promoting genes of the zebrafish are analyzed. The method can quantitatively evaluate the appetite regulating effect of medicine and health food, and the method steps are simple and time-saving.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

This invention relates to the technical field of functional foods and traditional Chinese medicine health products, specifically disclosing a medicinal and edible composition with weight-loss function, its preparation method, and its application. The composition comprises the following components in parts by weight: lotus leaf: 80–120 parts; hawthorn polyphenol complex: 50–70 parts; eucommia leaf: 100–140 parts; cassia seed: 20–40 parts; poria cocos powder: 20–40 parts; coix seed: 20–40 parts; green tea extract: 100–140 parts; white kidney bean: 40–60 parts; conjugated linoleic acid oil powder: 40–60 parts; turmeric powder: 40–60 parts. This invention overcomes the shortcomings of existing natural weight-loss products with their single mechanism of action. By combining components such as hawthorn polyphenol complex, eucommia leaf, coix seed, white kidney bean, and conjugated linoleic acid oil powder, it achieves a multi-faceted synergistic effect, from suppressing appetite and reducing absorption to promoting fat decomposition and energy metabolism.

The invention discloses a probiotic composition containing lactobacillus paracasei RX-LA302 with a weight losing effect as well as a preparation method and application of the probiotic composition. The lactobacillus paracasei RX-LA302 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number of the lactobacillus paracasei RX-LA302 is GDMCC No: 66820. The probiotic composition provided by the invention takes the lactobacillus paracasei RX-LA302 freeze-dried powder as a main active component, can significantly increase satiety, inhibit appetite, reduce caloric intake and realize healthy weight loss, is suitable for common people and overweight / obese people, and has a wide market prospect.

The invention discloses a long-acting polypeptide analogue and application thereof.The polypeptide analogue can target a GLP-1 receptor, a GIP receptor and an NPY2 receptor at the same time and has multiple biological functions, the advantages of GLP-1 in diabetes treatment can be brought into play, the positive effects of GIP in glycometabolism and lipid metabolism regulation and appetite inhibition are achieved, and the polypeptide analogue can be used for treating diabetes mellitus and treating diabetes mellitus and treating diabetes mellitus and treating diabetes mellitus and treating diabetes mellitus and treating diabetes mellitus and treating diabetes mellitus and treating diabetes mellitus. The effect of the PYY3-36 on regulating and controlling the appetite is fused. The multi-target synergistic effect is beneficial to optimization of sugar, fat and energy balance. The polypeptide analogue shows a wider application prospect in the field of preparation of drugs for preventing and treating metabolic syndromes, such as diabetes, obesity and other diseases.

The present invention relates to a composition for reducing appetite and / or promoting weight loss, the composition comprising, in a first compartment, a hydrophilic polymer selected from polysaccharides, their derivatives and mixtures thereof, a crosslinking compound, a foaming agent, and a foam stabilizing agent, and, in a second compartment, separate from the first compartment, an acid selected from tartaric acid, succinic acid, ascorbic acid, and mixtures thereof. The invention also relates to methods of administering the composition according to the invention to a human or animal subject.

The invention discloses application of 2-hydroxy-3-methylpentanoic acid in weight reduction and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The invention provides the application of the 2-hydroxy-3-methylvaleric acid and the derivative thereof in weight loss for the first time, and the compound can inhibit weight gain of a high-fat diet induced obesity model mouse, reduce body fat and reduce the fat cell area of the high-fat diet induced obesity model mouse. Compared with a GLP-1 receptor weight-reducing drug for reducing weight by inhibiting appetite, the compound 2-hydroxy-3-methylvaleric acid and the derivative thereof do not depend on appetite inhibition, and interfere and prevent obesity by accelerating fat metabolism, so that the effect of reducing weight is achieved; and side effects such as gastrointestinal discomfort and cardiovascular risk caused by appetite intervention are avoided. The invention provides a safe and effective new strategy for reducing weight and lipid.

Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

Methods and compositions for suppressing appetite are provided herein. In some embodiments, a method for suppressing appetite in a subject is provided, comprising the step of administering a composition comprising Bacteroides parabacteroides and Akkermansia to the subject.

To provide an oral composition having excellent glucagon-like peptide-1 secretion promoting action and appetite suppressing action.SOLUTION: The glucagon-like peptide-1 secretion-promoting composition contains Terminalia beryllia. The appetite suppressing composition contains Terminalia beryllia.SELECTED DRAWING: None

Provided herein are methods and compositions related to reducing / suppressing appetite. In some aspects, provided herein are methods of reducing / suppressing appetite in a subject by administering to the subject a composition comprising Parabacteroides and Akkermansia bacteria.

The present application provides a kind of ginger extract-containing weight loss composition and its preparation method and application, it is related to health care product technical field.The weight loss composition includes the following raw materials: ginger extract, cauliflower extract, acanthopanax extract, elderberry extract, phosphorus shrimp oil, red bean powder and vitamin.The present application significantly improves the weight loss and lipid-lowering effect of the composition by the interaction of specific raw materials ginger extract, cauliflower extract, elderberry extract and phosphorus shrimp oil, improves the metabolism of the body by adding specific compound vitamin, suppresses appetite by adding red bean powder, improves satiety, improves the immunity of the body by adding acanthopanax extract, improves exercise tolerance, cooperates with other components, further improves the weight loss and lipid-lowering effect, and has better stability.

The invention provides a weight-losing composition containing a ginger extract as well as a preparation method and application of the weight-losing composition, and relates to the technical field of health-care products. The weight-losing composition comprises the following raw materials: a fresh ginger extract, a cauliflower extract, an acanthopanax senticosus extract, an elderberry extract, krill oil, phaseolus calcaratus powder and vitamins. Through interaction of the specific raw materials including the ginger extract, the cauliflower extract, the elderberry extract and the krill oil, the weight-losing and lipid-lowering effects of the composition are remarkably improved, metabolism of a body is improved by adding the specific multivitamins, appetite is inhibited through the phaseolus calcaratus powder, satiety is improved, and the weight-losing and lipid-lowering effects of the composition are improved. The radix acanthopanacis senticosi extract is used for improving the immunity of the organism and improving the exercise tolerance, and is matched with other components, so that the weight-losing and lipid-lowering effects are further improved, and the stability is better.

The invention discloses application of 2-hydroxy-3-methylbutyric acid in weight reduction and lipid reduction, and belongs to the fields of biological medicine manufacturing, biological medicine application and functional food development. The invention provides the application of the 2-hydroxy-3-methylbutyric acid and the derivative thereof in weight loss for the first time, and the compound can inhibit the weight gain of a high fat diet induced obesity model mouse, reduce body fat and reduce the fat cell area of the high fat diet induced obesity model mouse. Compared with a GLP-1 receptor weight-reducing medicine for reducing weight by inhibiting appetite, the compound 2-hydroxy-3-methylbutyric acid and the derivative thereof do not depend on appetite inhibition, and interfere and prevent obesity by accelerating fat metabolism, so that the weight-reducing effect is achieved; and side effects such as gastrointestinal discomfort and cardiovascular risk caused by appetite intervention are avoided. The invention provides a safe and effective new strategy for reducing weight and lipid.